Cargando…
CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA
INTRODUCTION: Olfactory neuroblastoma (ONB) is a rare type of malignancy that infiltrates and propagates from the nasal cavity to the anterior skull base and into the cranium. Various treatment strategies have been used at different institutions and time of treatment. Although the staging system pro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213084/ http://dx.doi.org/10.1093/noajnl/vdz039.180 |
_version_ | 1783531725335298048 |
---|---|
author | Motegi, Hiroaki Yamaguchi, Shigeru Ishi, Yukitomo Endo, Shogo Kobayashi, Hiroyuki Terasaka, Shunsuke Suzuki, Masanobu Nakamaru, Yuji Homma, Akihiro Houkin, Kiyohiro |
author_facet | Motegi, Hiroaki Yamaguchi, Shigeru Ishi, Yukitomo Endo, Shogo Kobayashi, Hiroyuki Terasaka, Shunsuke Suzuki, Masanobu Nakamaru, Yuji Homma, Akihiro Houkin, Kiyohiro |
author_sort | Motegi, Hiroaki |
collection | PubMed |
description | INTRODUCTION: Olfactory neuroblastoma (ONB) is a rare type of malignancy that infiltrates and propagates from the nasal cavity to the anterior skull base and into the cranium. Various treatment strategies have been used at different institutions and time of treatment. Although the staging system proposed by Kadish is commonly adopted has not proven useful for predicting prognosis or choosing among treatment strategies. Factors to be considered have increased accordingly, for example, whether to perform ESS alone or in combination with craniotomy, whether to try preserving the olfactory sense and whether to use neoadjuvant chemotherapy. In this study, we reviewed ONB cases treated at our institution to propose a new classification system to help determine treatment strategies. METHODS: Thirty-four patients treated at Hokkaido University were included. Stages of craniocaudal progression were defined as Nasally/Paranasally localized (NP), Frontal Base progression (FB), and Brain invasion (BI). Stages of lateral progression were defined as Midline (M) or Lateral extension (L), and Unilateral (U) or Bilateral (B). RESULTS: Between 2008 and 2016, patients at the BI stage were proactively treated with neoadjuvant chemotherapy and achieved long-term survival (mean overall survival, 64.2 months). However, no standard way of choosing among treatment options was established. M-stage patients underwent concurrent craniotomy. From 2017 onwards, 5 patients were treated according to the new classification system. All were FB-M cases, including 4 cases of B disease, in which ESS alone followed by radiotherapy was used. One patient in the FB-M-U category underwent unilateral resection and the olfactory sense was preserved. In general, the treatment with ESS alone appeared to be preferred for M disease, and surgery after neoadjuvant chemotherapy was advisable for BI cases. CONCLUSION: The result suggests that the new classification system is helpful to decide the treatment strategy according to the progression of ONB. |
format | Online Article Text |
id | pubmed-7213084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72130842020-07-07 CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA Motegi, Hiroaki Yamaguchi, Shigeru Ishi, Yukitomo Endo, Shogo Kobayashi, Hiroyuki Terasaka, Shunsuke Suzuki, Masanobu Nakamaru, Yuji Homma, Akihiro Houkin, Kiyohiro Neurooncol Adv Abstracts INTRODUCTION: Olfactory neuroblastoma (ONB) is a rare type of malignancy that infiltrates and propagates from the nasal cavity to the anterior skull base and into the cranium. Various treatment strategies have been used at different institutions and time of treatment. Although the staging system proposed by Kadish is commonly adopted has not proven useful for predicting prognosis or choosing among treatment strategies. Factors to be considered have increased accordingly, for example, whether to perform ESS alone or in combination with craniotomy, whether to try preserving the olfactory sense and whether to use neoadjuvant chemotherapy. In this study, we reviewed ONB cases treated at our institution to propose a new classification system to help determine treatment strategies. METHODS: Thirty-four patients treated at Hokkaido University were included. Stages of craniocaudal progression were defined as Nasally/Paranasally localized (NP), Frontal Base progression (FB), and Brain invasion (BI). Stages of lateral progression were defined as Midline (M) or Lateral extension (L), and Unilateral (U) or Bilateral (B). RESULTS: Between 2008 and 2016, patients at the BI stage were proactively treated with neoadjuvant chemotherapy and achieved long-term survival (mean overall survival, 64.2 months). However, no standard way of choosing among treatment options was established. M-stage patients underwent concurrent craniotomy. From 2017 onwards, 5 patients were treated according to the new classification system. All were FB-M cases, including 4 cases of B disease, in which ESS alone followed by radiotherapy was used. One patient in the FB-M-U category underwent unilateral resection and the olfactory sense was preserved. In general, the treatment with ESS alone appeared to be preferred for M disease, and surgery after neoadjuvant chemotherapy was advisable for BI cases. CONCLUSION: The result suggests that the new classification system is helpful to decide the treatment strategy according to the progression of ONB. Oxford University Press 2019-12-16 /pmc/articles/PMC7213084/ http://dx.doi.org/10.1093/noajnl/vdz039.180 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Motegi, Hiroaki Yamaguchi, Shigeru Ishi, Yukitomo Endo, Shogo Kobayashi, Hiroyuki Terasaka, Shunsuke Suzuki, Masanobu Nakamaru, Yuji Homma, Akihiro Houkin, Kiyohiro CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title | CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title_full | CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title_fullStr | CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title_full_unstemmed | CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title_short | CS-09 PROPOSAL OF A NEW CLASSIFICATION FOR DETERMINING THERAPEUTIC STRATEGY ACCORDING TO THE PROGRESSION OF OLFACTORY NEUROBLASTOMA |
title_sort | cs-09 proposal of a new classification for determining therapeutic strategy according to the progression of olfactory neuroblastoma |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213084/ http://dx.doi.org/10.1093/noajnl/vdz039.180 |
work_keys_str_mv | AT motegihiroaki cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT yamaguchishigeru cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT ishiyukitomo cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT endoshogo cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT kobayashihiroyuki cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT terasakashunsuke cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT suzukimasanobu cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT nakamaruyuji cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT hommaakihiro cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma AT houkinkiyohiro cs09proposalofanewclassificationfordeterminingtherapeuticstrategyaccordingtotheprogressionofolfactoryneuroblastoma |